Health
Novartis to Buy Anthos Therapeutics for Up to $3.1 Billion
- Swiss drugmaker to pay as much as $2.15 billion in milestones
- Novartis started Anthos in 2019 together with Blackstone
This article is for subscribers only.
Novartis AG agreed to buy US biotech Anthos Therapeutics for as much as $3.1 billion to gain a preventative stroke medicine that could be the first of its kind.
The Swiss drugmaker will pay $925 million upfront and as much as $2.15 billion more if the experimental drug meets certain regulatory and sales milestones, it said Tuesday. Blackstone Inc.’s life sciences arm started Anthos with Novartis, whose labs devised the medicine it’s now getting back.